Arkos Global Advisors Trims Position in Eli Lilly and Company (NYSE:LLY)

Arkos Global Advisors decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 8.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 276 shares of the company’s stock after selling 25 shares during the period. Arkos Global Advisors’ holdings in Eli Lilly and Company were worth $250,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Aveo Capital Partners LLC increased its holdings in shares of Eli Lilly and Company by 8.2% in the fourth quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock valued at $1,178,000 after purchasing an additional 153 shares during the period. Gryphon Financial Partners LLC grew its position in Eli Lilly and Company by 19.4% in the 4th quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock valued at $1,355,000 after buying an additional 377 shares during the last quarter. J. W. Coons Advisors LLC increased its stake in Eli Lilly and Company by 4.0% in the 4th quarter. J. W. Coons Advisors LLC now owns 2,324 shares of the company’s stock valued at $1,355,000 after buying an additional 90 shares during the period. Relative Value Partners Group LLC raised its position in Eli Lilly and Company by 3.5% during the 4th quarter. Relative Value Partners Group LLC now owns 1,791 shares of the company’s stock worth $1,044,000 after buying an additional 60 shares during the last quarter. Finally, Brown Brothers Harriman & Co. raised its position in Eli Lilly and Company by 0.5% during the 4th quarter. Brown Brothers Harriman & Co. now owns 17,074 shares of the company’s stock worth $9,953,000 after buying an additional 80 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Citigroup began coverage on Eli Lilly and Company in a report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price objective on the stock. Deutsche Bank Aktiengesellschaft raised Eli Lilly and Company from a “hold” rating to a “buy” rating and increased their target price for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Finally, BMO Capital Markets upped their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $877.50 on Friday. The company has a 50-day moving average of $896.10 and a two-hundred day moving average of $842.91. The stock has a market cap of $833.98 billion, a P/E ratio of 129.23, a PEG ratio of 2.78 and a beta of 0.42. Eli Lilly and Company has a 12-month low of $516.57 and a 12-month high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, research analysts predict that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 423,559 shares of company stock valued at $393,136,808 over the last quarter. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.